The American regulatory agency approved the pharmaceutical company’s oral medicine Eli Lilly for adults with obesity or overweight associated with related health conditions. Pill Foundayo, taken once a day, represents a new option in the GLP-1 drug segment. The Indianápolis-based company plans to begin shipping the product via direct-to-consumer platform LillyDirect next Monday. Availability in pharmacies and telehealth platforms should occur shortly after.
People with insurance coverage can access the treatment for US$25 a month with a coupon from the manufacturer. Aqueles who pay out of pocket will face prices between US$149 and US$349, depending on the dose chosen. Approval occurred under the FDA’s accelerated review program, which allowed progress in about three months after the application was submitted.
Details of effectiveness and comparison with other treatments
Phase 3 clinical trials demonstrated that patients who adhered to treatment with the highest dose of Foundayo lost an average of 12.4% of their body weight over 72 weeks. Esse result is equivalent to around 12.4 kilos in a person weighing 100 kilos initially. The group that received placebo recorded an average loss of just 0.9% over the same period.
The pill does not achieve the same level of weight reduction observed with the weekly injection Zepbound, from Eli Lilly itself, which exceeds 20% in consistent studies. Mesmo Therefore, the convenience of an oral formulation without time, food or water restrictions sets the product apart. Especialistas highlight that the daily option may attract patients who prefer to avoid injections or seek greater flexibility in their daily lives.
- Foundayo can be taken at any time without the need for an empty stomach.
- Unlike the oral version of Wegovy, it does not require a limited amount of water in the morning.
- Small molecule formulation facilitates global scale production without stringent cold chain requirements.
Drug launch strategy and accessibility
Eli Lilly licensed the orforglipron molecule from Japanese company Chugai in 2018 for an initial US$50 million. Desde So, the company has invested more than US$55 billion in production capacity since 2020, including new facilities and expansions of existing plants. The objective is to guarantee sufficient supply to meet global demand as soon as there are regulatory approvals in other countries.
The company’s CEO, Dave Ricks, stated that the pill allows for greater scalability than injectable peptides. Ele highlighted the possibility of launching the product globally soon after approvals, unlike previous oral options that face international distribution limitations. The company has submitted the drug for evaluation in more than 40 countries and expects approvals over the next 12 months.
Eli Lilly also positions Foundayo as an alternative for weight maintenance after patients reach goals with injectables. Estudos indicate that switching to the pill helps sustain results with less weight gain compared to complete treatment interruptions.
Competition in the glp-1 market and initial reaction to demand
The approval puts Eli Lilly in direct competition with the oral version of Wegovy, from Novo Nordisk, recently launched in Estados Unidos. Relatos initials indicate that the competitor’s pill registered more than 600 thousand prescriptions in March alone, exceeding initial expectations. Executivos from both companies note that oral formats tend to expand the total market rather than just migrating injectable users.
Doctors report that price continues to be a decisive factor when choosing between the available options. Starting in July 2026, eligible beneficiaries of Medicare will be able to access GLP-1 obesity medications for $50 per month under agreements reached with the current administration. Analistas consider that the commercial success of Foundayo will be important for the recovery of Eli Lilly shares, which have registered a drop of around 14% in the year to date.
The pill also showed improvements in markers of cardiovascular risk, such as reduced waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure. Esses Benefits occurred at all doses tested in the ATTAIN clinical programs.
Technical aspects and production of the new treatment
Unlike the peptides used in Zepbound and Wegovy, Foundayo is a small molecule. Essa feature reduces manufacturing barriers and may limit the viability of generic versions in markets like Índia where injectables face production challenges. The company emphasizes that the oral format without administration restrictions represents a practical advance for patients on a daily basis.
The most common side effects include nausea, constipation, diarrhea, vomiting and abdominal pain, similar to the profile of other medications in the GLP-1 class. The leaflet warns of a possible risk of thyroid tumors, although the medicine is not recommended for children. Eli Lilly recommends combined use with a reduced-calorie diet and increased physical activity.
The company plans to monitor prescriptions in the first few weeks to gauge actual adoption of the product. Analistas market projects significant sales for Foundayo by 2030, although lower than estimates for Zepbound and Mounjaro, which continue to be the company’s main revenue drivers in the segment.
International expansion and next steps for eli lilly
The global strategy foresees sequential launches according to regulatory approvals. The absence of complex storage requirements should facilitate distribution in regions with limited infrastructure. Executivos highlight that the medicine can reach populations that currently do not access injectable treatments for logistical reasons or personal preference.
Eli Lilly continues to invest in additional studies to expand indications for orforglipron, including type 2 diabetes, obstructive sleep apnea and other associated conditions. Esses developments aim to consolidate the company’s position in the growing market for weight management and metabolic medicines.